SECsense Logo

Axsome Therapeutics 8-K Report: Key Insights from February 10, 2025 Filing

$AXSM
Form 8-K
Filed on: 2025-02-10
Source
Axsome Therapeutics 8-K Report: Key Insights from February 10, 2025 Filing

Based on the provided XML segment from the financial report, here are the key pieces of information extracted:

  1. Entity Information:
  • Company Name: Axsome Therapeutics, Inc.
  • CIK Number: 0001579428
  • SEC File Number: 001-37635
  • Tax ID: 45-4241907
  • Address: One World Trade Center, 22nd Floor, New York, NY 10007
  • Phone Number: (212) 332-3241
  1. Filing Information:
  • Filing Type: 8-K (Current Report)
  • Filing Date: February 10, 2025
  1. Stock Information:
  • Common Stock: Par Value of $0.0001 per share
  • Ticker Symbol: AXSM
  • Exchange: NASDAQ
  1. Period of Report:
  • Start Date: February 10, 2025
  • End Date: February 10, 2025

Insights:

  • The report is a current report (8-K), which typically contains significant events or corporate changes that are of interest to investors.
  • The filing date and the period of reporting are the same, indicating that the report is likely addressing an event that occurred on that date.
  • The company is publicly traded on NASDAQ, which includes the relevant stock information including par value and ticker symbol, crucial for investors tracking stock performance.

Conclusion:

This information is essential for investors and analysts to monitor Axsome Therapeutics, Inc.'s corporate developments, assess its financial health, and make informed investment decisions. The specifics regarding the filing type and date suggest that stakeholders should pay attention to any events or announcements reflected in this report.